GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

darunavir   Click here for help

GtoPdb Ligand ID: 11243

Abbreviated name: DRV
Synonyms: Prezista® | TMC114 | UIC-94017
Approved drug PDB Ligand
darunavir is an approved drug (FDA (2006), EMA (2007))
Compound class: Synthetic organic
Comment: Darunavir is a second-generation human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) [2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: darunavir

darunavir is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 13
Topological polar surface area 148.8
Molecular weight 547.24
XLogP 2.28
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)C
Isomeric SMILES CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)C
InChI InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
InChI Key CJBJHOAVZSMMDJ-HEXNFIEUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Darunavir is used in the treatment of HIV-1 infection and for postexposure prophylaxis (off-label). To increase its bioavailability and half-life, darunavir is coadministered with other antiretroviral agents such as ritonavir or cobicistat. The compound is also approved as a component of Symtuza®, a once daily anti-HIV therapy that contains darunavir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate.

SARS-CoV-2 and COVID-19: The antiviral activity and safety of darunavir/cobicistat for treating COVID-19 pneumonia has been evaluated in a Phase 3 clinical trial (NCT04252274). This trial found no significant benefit for patients with severe COVID-19, when compared to standard therapy [1].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Darunavir, like other HIV PIs, competitively inhibits the action of the viral aspartyl protease, an enzyme essential for the proteolytic cleavage of nascent polypeptide precursors into mature viral proteins. The compound was designed to have a high barrier to resistance in an attempt to maintain activity against multidrug-resistant HIV-1 strains.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04252274 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 Phase 3 Interventional Shanghai Public Health Clinical Center
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)